Keri Schaubert was quoted in Bloomberg Law discussing drug patent lawsuits that took a 21% dive from this time last year, a “perfect storm” that traces back to 2016 when the FDA only approved a handful of new drugs. “There’s just far fewer opportunities for generics to take advantage of this year,” said Keri. “When you combine that with COVID-19, you have the perfect storm.” Only 179 drug patent lawsuits, known as Hatch-Waxman cases, were filed as of Aug. 27, down from the 227 cases docketed by Aug. 31, 2019, according to a Bloomberg tracker.

To read more of this article, click here.